Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients.

Jixue Zou,Peixin Huang,Ningling Ge,Xin Xu,Yanhong Wang,Lan Zhang,Yi Chen

Journal of gastrointestinal oncology（2022）

引用 1|浏览16

暂无评分

摘要

The combination of anti-PD-1 antibodies and lenvatinib may benefit patients with unresectable HCC who progressed on lenvatinib. This study provides a real-world data and treatment choice for patients progressed with lenvatinib.

查看译文

关键词

Hepatocellular carcinoma (HCC),adverse events,anti-PD-1 antibodies,lenvatinib,tumor response

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要